Affinity purification methods involving imidazole elution
    62.
    发明授权
    Affinity purification methods involving imidazole elution 失效
    涉及咪唑洗脱的亲和纯化方法

    公开(公告)号:US5726293A

    公开(公告)日:1998-03-10

    申请号:US250317

    申请日:1994-05-27

    申请人: Brian Seed

    发明人: Brian Seed

    摘要: Disclosed is a method of isolating a protein from a sample, involving (i) providing a first molecule which is capable of forming an affinity complex with the protein; (ii) contacting the sample with the first molecule under conditions which allow affinity complex formation; (iii) isolating the complex; (iv) treating the complex with imidazole to disrupt the complex, causing the release of the protein from the complex; and (v) isolating the protein. According to one embodiment, imidazole is used as a very gentle elution reagent to disrupt a protein A-antibody fusion protein complex, a technique which has general application for the isolation of antibodies or recombinant antibody fusion proteins.

    摘要翻译: 公开了一种从样品中分离蛋白质的方法,其包括(i)提供能够与蛋白质形成亲和复合物的第一分子; (ii)在允许形成亲和性复合物的条件下使样品与第一分子接触; (iii)分离复合物; (iv)用咪唑处理复合物以破坏复合物,引起蛋白质从络合物的释放; 和(v)分离蛋白质。 根据一个实施方案,咪唑用作非常温和的洗脱剂以破坏蛋白质A抗体融合蛋白复合物,该技术具有分离抗体或重组抗体融合蛋白的一般应用。

    Method of preparing fusion proteins
    65.
    发明授权
    Method of preparing fusion proteins 失效
    融合蛋白的制备方法

    公开(公告)号:US5358857A

    公开(公告)日:1994-10-25

    申请号:US73508

    申请日:1993-06-09

    IPC分类号: C07K14/62 C12N15/12 C12N15/62

    摘要: Fusion proteins are obtained in high yields if a mixed oligonucleotide is constructed which codes for the ballast constituent of the fusion protein. The oligonucleotide mixture is introduced in a vector in such a manner that it is functionally linked to a regulatory region and to the structural gene for the desired protein. Appropriate host cells are transformed with the plasmid population obtained in this manner and the clones producing a high yield of coded fusion protein are selected.

    摘要翻译: 如果构建编码融合蛋白的镇流成分的混合寡核苷酸,则以高产率获得融合蛋白。 将寡核苷酸混合物以这样的方式引入载体中,使得其功能上连接到调节区域和所需蛋白质的结构基因。 用以这种方式获得的质粒群转化合适的宿主细胞,并选择产生高产量的编码融合蛋白的克隆。

    ENGINEERED THIOREDOXIN-LIKE FOLD PROTEINS
    67.
    发明申请
    ENGINEERED THIOREDOXIN-LIKE FOLD PROTEINS 有权
    工程化的硫氧还蛋白样蛋白

    公开(公告)号:US20140113832A1

    公开(公告)日:2014-04-24

    申请号:US14006237

    申请日:2012-03-29

    IPC分类号: C07K14/00 G01N33/68

    摘要: The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins.

    摘要翻译: 本发明的特征在于基于硫氧还蛋白样折叠蛋白质结构域的组合物,其描述为工程化硫氧还蛋白样折叠蛋白(ETRX)。 这些蛋白质包括一个或多个人工多样化的硫氧还蛋白样折叠蛋白质结构域; 每个结构域可以源于相同或不同的硫氧还蛋白样折叠蛋白结构域。 本发明的特征还包括用于鉴定和制备具有额外序列变异的靶结合,环多样化ETRX的富集组合物以提高亲和力,稳定性,选择性或溶解度的方法。 本发明还特征在于用补体基团,聚合物,蛋白质,核酸,碳水化合物,金属,天然或合成的小分子和毒素取代的ETRX的组合物。

    COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
    70.
    发明申请
    COMBINATION THERAPY FOR THE TREATMENT OF DIABETES 有权
    用于治疗糖尿病的组合治疗

    公开(公告)号:US20110312946A1

    公开(公告)日:2011-12-22

    申请号:US13165549

    申请日:2011-06-21

    摘要: The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.

    摘要翻译: 本发明提供了治疗或减少,预防或抑制糖尿病症状和/或降低血浆中HbA1c水平的方法,方法是将治疗或次治疗剂量的替苯西汀和舍曲林联合给有需要的受试者。